CTHRC1 is a Potential Prognostic Biomarker and Correlated with Macrophage Infiltration in Breast Cancer
Open Access
- 1 June 2022
- journal article
- research article
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 15, 5701-5713
Abstract
Background: Tumor immune cell infiltration is closely associated with the occurrence and development of tumors. Collagen triple helix repeats containing 1 (CTHRC1), a regulator of collagen expression and cell migration, is involved in the metastasis and invasion of tumors. However, the role of CTHRC1 in breast cancer remains unclear. This study aimed to investigate the prognostic value of CTHRC1, and further explore its association with immune infiltration in breast cancer. Methods: CTHRC1 expression pattern and prognostic value were analyzed using ONCOMINE, PrognoScan, GEPIA, and Kaplan–Meier Plotter databases. We then detected CTHRC1 mRNA levels in breast cancer tissues and paired normal breast tissues by Q-PCR. Subsequently, the University of California Santa Cruz (UCSC) database was used to determine the methylation status of CTHRC1. Furthermore, CTHRC1 mutations were investigated using the Catalogue of Somatic mutations in Cancer (COSMIC) and cBioPortal databases. We also assessed the correlation between CTHRC1 expression and immune cell infiltration using TIMER. In addition, The relationship of CTHRC1 expression with the immune marker sets of various immune cells was evaluated using GEPIA and TIMER. Results: CTHRC1 was highly expressed in a variety of tumors, including breast cancer. Elevated CTHRC1 expression was related to a poor prognosis. Notably, CTHRC1 expression was significantly associated with macrophage infiltration, especially the immune infiltration gene marker set of M2. Copy number variations, DNA mutations and methylation states might be potential mechanisms for regulating CTHRC1 expression. Protein digestion and absorption, human papillomavirus infection, ECM-receptor interaction, focal adhesion, and PI3K-Akt signaling pathways were identified as the potential CTHRC1-driven signaling pathways. Conclusion: These findings suggest that CTHRC1 could be a promising immune-related biomarker for the treatment of breast cancer patients.Keywords
This publication has 45 references indexed in Scilit:
- Collagen triple helix repeat containing 1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation and motilityInternational Journal of Oncology, 2014
- The M1 and M2 paradigm of macrophage activation: time for reassessmentF1000Prime Reports, 2014
- Collagen Triple Helix Repeat Containing-1 (CTHRC1) Expression in Invasive Ductal Carcinoma of the Breast: The Impact on Prognosis and Correlation to Clinicopathologic FeaturesPathology and Oncology Research, 2013
- Exploring the full spectrum of macrophage activationNature Reviews Immunology, 2008
- Cthrc1 Selectively Activates the Planar Cell Polarity Pathway of Wnt Signaling by Stabilizing the Wnt-Receptor ComplexDevelopmental Cell, 2008
- Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysisBMC Cancer, 2007
- Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression ProfilesNeoplasia, 2007
- Expression analysis of the novel gene collagen triple helix repeat containing-1 (Cthrc1)Gene Expression Patterns, 2006
- Aberrant Expression of Collagen Triple Helix Repeat Containing 1 in Human Solid CancersClinical Cancer Research, 2006
- Collagen Triple Helix Repeat Containing 1, a Novel Secreted Protein in Injured and Diseased Arteries, Inhibits Collagen Expression and Promotes Cell MigrationCirculation Research, 2005